All In Biotech

Drug Trial Radar · NCT00413075

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

Open Label, Dose Escalation Trial of Oral PXD101 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 8, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

121

Actual

Start

Jun 2006

Primary completion

Aug 2011

Study completion Aug 2011

Sponsor

Lead sponsor
Valerio TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Spectrum Pharmaceuticals, Inc
First posted
Dec 19, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I dose escalation study of PXD101 administered orally. Oral belinostat will be given once or twice daily at various dosing schedules to patients with solid tumors. Doses will be escalated until the maximum tolerated dose (MTD) is identified. In parallel, a cohort of lymphoma patients will be given oral belinostat on a discontinuous once daily dosing schedule.

Conditions

  • Solid Tumor
  • Lymphoma

Interventions

  • oral belinostatDrug

    oral belinostat dosed once or twice daily at continuous and discontinuous dosing schedules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety, tolerability and maximum tolerated dose of orally administered PXD101 for each cohortTime frame: throughout the study

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • Yale New Haven Hospital

    New Haven, Connecticut

  • Columbia University - Herbert Irving Cancer Center

    New York, New York

  • New York University Cancer Institute

    New York, New York

  • M.D. Anderson Cancer Center

    Houston, Texas

  • Research Facility

    Copenhagen, Copenhagen, Denmark

  • Research Facility

    London, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.